MARKET

PHAT

PHAT

Phathom Pharmaceuticals, Inc.
NASDAQ
4.840
+0.430
+9.75%
After Hours: 4.910 +0.07 +1.45% 17:22 03/17 EDT
OPEN
4.420
PREV CLOSE
4.410
HIGH
4.890
LOW
4.400
VOLUME
921.34K
TURNOVER
--
52 WEEK HIGH
19.71
52 WEEK LOW
4.070
MARKET CAP
337.04M
P/E (TTM)
-0.9146
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PHAT last week (0310-0314)?
Weekly Report · 13h ago
2 Growth Stocks to Buy Now With 367% to 410% Upside
Barchart · 15h ago
Wasatch Ultra Growth Fund Q4 2024 Commentary
Seeking Alpha · 1d ago
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic?
Simply Wall St · 6d ago
Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges
TipRanks · 6d ago
Phathom Pharmaceuticals Is Maintained at Neutral by Goldman Sachs
Dow Jones · 03/10 17:46
Phathom Pharmaceuticals Price Target Cut to $12.00/Share From $18.00 by Goldman Sachs
Dow Jones · 03/10 17:46
Goldman Sachs Maintains Neutral on Phathom Pharmaceuticals, Lowers Price Target to $12
Benzinga · 03/10 17:36
More
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Webull offers Phathom Pharmaceuticals Inc stock information, including NASDAQ: PHAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHAT stock methods without spending real money on the virtual paper trading platform.